Rick Simpson Oil (RSO) in Apache County, Arizona: The Complete Guide by OilWell Cannabis

Welcome, Apache County. We see you. Out there in the high desert, across the vast stretches of the Navajo Nation, through the red-rock canyons and piñon-juniper woodlands that define this land. We know the challenges you face—chronic pain from decades of physical work, the isolation that comes with rural living, the distance from major medical centers in Phoenix or Albuquerque, and the deep, community-rooted desire for healing that respects both modern science and traditional wisdom.

We are OilWell Cannabis, and we built this guide for you. Not as outsiders looking in, but as people who understand what it means to be let down by a system that should have helped. Our founder, Colin Valencia, grew up in the borderlands of McAllen, Texas—a place where violence and poverty taught him early that healing often comes from unexpected places. Our company’s origin story begins with a paralyzed dog named Bentley, a question that changed everything (“You’ve moved how many tons of weed and you’ve never heard of CBD?”), and a refusal to accept that suffering is inevitable.

This is not snake oil. This is not hope sold in a bottle. This is real science, real transparency, and real formulas—published openly so you can decide for yourself whether this path is right for you or your loved ones.

About Rick Simpson and Traditional Rick Simpson Oil

Who is Rick Simpson?

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine could not resolve. The medications he was prescribed either failed to help or made his condition worse. Cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

This story resonates across Apache County, where many of you have faced similar frustration—whether from workplace injuries in ranching, construction, or the energy sector; from chronic pain after years of physical labor; or from the aftermath of accidents on remote roads where medical response is hours away. When the system says “no,” people find their own answers.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s advocacy, even though its findings were never replicated in controlled human cancer trials .

The Pivotal Moment: Simpson’s 2003 Skin Cancer Story

The pivotal moment came in 2003. Simpson reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and reported that the bumps disappeared within four days.

Important context: No independent medical verification of this outcome has been published. No biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. This account is presented as Simpson’s personal testimony—not medical evidence—but it is historically significant as the catalyst for a global movement around concentrated cannabis oil .

For families in Apache County facing skin cancer diagnoses—which are notably higher here due to intense sun exposure at high altitude—this story carries weight. We understand why it resonates. But we also understand the responsibility to separate personal testimony from clinical proof. That distinction is critical when you’re making decisions about your health or your family’s health in a place like Apache County, where specialized dermatology care may require a four-hour drive to Flagstaff or Phoenix.

The Crusade: Spreading the Oil

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community—no charge, no profit motive. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more .

This free-distribution model became the moral foundation of the RSO movement. Simpson believed medicine should be accessible to everyone, not locked behind corporate pricing or regulatory gatekeeping.

That ethos echoes across the Navajo Nation and rural Apache County communities, where healthcare access is already strained and the cost of travel for specialist care puts essential treatment out of reach for many families. The idea that someone would give away medicine rather than profit from suffering is powerful here.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, which became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational—many people’s first introduction to concentrated cannabis oil as medicine .

The Legal Conflict

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and 2009. He was charged with cannabis cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, continuing his advocacy from Croatia and later the Netherlands .

This legal history is painfully familiar to many in Arizona. Before Proposition 207 legalized recreational cannabis in 2020, countless Apache County residents faced life-altering consequences for cannabis possession. The criminal justice system’s approach to cannabis has created generational trauma—particularly within Native American communities who have seen disproportionate enforcement.

The 2012 Book and Website

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his personal experience, oil-making process, and philosophical views. He maintained phoenixtears.ca as his primary online platform .

Throughout his career, Simpson’s position remained consistent: he maintained that cannabis oil could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect financial interests .

Important context: Simpson’s conspiratorial framing reflects a worldview shared by many in the early cannabis movement. We present it here to understand RSO’s cultural significance, not to endorse or critique it. The evidence-based assessment of his medical claims follows below.

The Traditional RSO Protocol: Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions .

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of rice—roughly 10 to 15 milligrams of oil—taken three times per day. Total daily intake: approximately 30 to 45 milligrams. The initial doses must be very small to allow the body to begin adjusting to THC’s psychoactive effects.
• Weeks 2-5: Double the dose approximately every four days. By the end of this escalation period (four to five weeks), the target is to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5-12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, until the full 60 grams have been consumed.

For Apache County residents considering this protocol: understand that 1 gram of traditional RSO daily represents approximately 600 to 900 milligrams of delta-9 THC—doses far exceeding anything studied in controlled clinical settings. This is not a safe starting point, especially for those new to cannabis or managing complex health conditions.

Administration Methods

• Oral (primary): Place the dose directly under the tongue (sublingual) or swallow it. Simpson considered oral ingestion most important for systemic absorption and primary treatment of internal cancers and other systemic conditions.
• Topical (secondary): For skin cancers and external lesions, apply oil directly to the affected area, cover with a bandage, and change every three to four days. Simpson combined topical application with oral dosing for skin cancers.
• Inhalation (not recommended as primary): Simpson acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for sustained, high-dose exposure he considered therapeutically essential.

Tolerance and Psychoactive Effects

• Simpson maintained patients would develop significant tolerance to THC’s psychoactive effects within approximately three to four weeks of consistent dosing at escalating levels.
• He considered euphoric, sedating, or disorienting effects a minor and temporary side effect, urging patients not to let the high discourage them from continuing.
• He recommended initial doses at night or before bed to sleep through the most intense psychoactive effects during early titration.
• Simpson recommended patients avoid driving or operating machinery during titration and inform family members about what to expect.

Post-Protocol Maintenance

After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely, for long-term health and cancer prevention.

Dietary and Lifestyle Recommendations

Simpson also advocated for dietary changes—reducing sugar, avoiding processed foods, improving overall nutrition—though this advice was secondary and general compared to his detailed oil protocol.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or formal research. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or well-documented case series evaluating this 60-gram/90-day protocol for any cancer type or condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely depending on starting plant material and extraction technique.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil daily. Assuming traditional RSO contained 60-90% THC, this translates to approximately 600 to 900 milligrams of delta-9 THC daily—far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the GENERAL KNOWLEDGE section [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as primary treatment—potentially in place of proven therapies—introduces harm beyond the oil itself.

For Apache County residents: If you’re considering RSO for cancer support, please consult with oncologists at Tuba City Regional Health Care Corporation, Chinle Comprehensive Health Care Facility, or Sage Memorial Hospital. These protocols should complement, not replace, proven cancer treatments.

What is Traditional Rick Simpson Oil—the Product?

Traditional RSO refers to the specific type of concentrated cannabis oil Simpson made and advocated for. It was defined by his method and materials, not by lab specifications or regulatory standards .

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment. He grew his own cannabis or sourced it from trusted growers. There was no strain standardization—starting material varied by availability and growing season.

In Apache County, where cannabis cultivation knowledge runs deep in some communities, this variability would be immediately recognized. A strain that works for one person’s pain might not work for another’s nausea—and Simpson had no way to control for this.

Extraction Solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid or Varsol. He later endorsed 99% isopropyl alcohol as an alternative. He warned against butane or acetone due to safety concerns. Neither naphtha nor isopropyl alcohol is food-grade, creating significant safety issues.

Extraction Process

1. Dry cannabis placed in a container (typically a bucket)
2. Covered with solvent and agitated for several minutes to dissolve cannabinoids
3. Solvent poured off through filter (cheesecloth) into collection vessel
4. Process repeated with fresh solvent on same plant material
5. Combined solvent washes placed in rice cooker or open-vessel heating device
6. Solvent evaporated at relatively low heat (60-80°C for naphtha, ~82°C for isopropyl)
7. Thick, dark oil remained at bottom of vessel
8. Final oil transferred into oral syringes for storage and dosing

For Apache County residents considering DIY extraction: the fire risk is extreme in our dry climate. The solvents are toxic. This is not worth the danger when legal, lab-tested alternatives exist.

Appearance and Physical Characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil with strong cannabis odor and possible faint solvent-residual smell. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC: Heat converted essentially all THCa into delta-9 THC. Traditional RSO was an activated, THC-dominant product.
• Naturally occurring minor cannabinoids: Whatever CBD, CBN, CBC, CBG, and others the source strain contained were present at natural ratios, but not controlled, measured, or targeted.
• No ratio control: The profile was entirely determined by genetics and growing conditions.
• Estimated THC content: Depending on starting material, traditional RSO likely ranged from 60-90% total THC by weight, though never lab-verified in traditional production.

Terpene Content

Minimal to none. The combination of solvent extraction and high-heat evaporation (which volatilizes terpenes at temperatures well below cannabinoid degradation) meant traditional RSO was effectively stripped of terpene content. This is a significant distinction from modern formulations that deliberately preserve terpenes.

For Apache County residents familiar with the aromatic complexity of traditional plant medicines, this terpene loss represents a major limitation of traditional RSO.

Standardization and Testing

None. Every batch was different because it depended on starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature/duration, and the individual maker’s process. There was no Certificate of Analysis, no cannabinoid quantification, no contaminant screening.

Residual Solvent Risk

This is one of the most significant safety concerns. Naphtha and isopropyl alcohol are not food-grade. Naphtha may contain benzene, toluene, xylene, and other toxic compounds. Incomplete solvent purging—which is very difficult to verify without lab testing—leaves potentially harmful residues.

Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address this problem. For Apache County residents, this matters deeply. We have enough environmental health concerns—from uranium mining legacy to water quality issues—without adding solvent contamination to the list.

Simpson’s Claims vs. the Evidence Record

Rick Simpson made expansive therapeutic claims: RSO could cure cancer and was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and more .

It’s important to evaluate these claims against the actual evidence base, using the same standards applied throughout this document.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and informally gathered testimonials—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows

The preclinical cannabinoid-cancer literature exists and is scientifically interesting:

• In vitro studies demonstrate THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis in certain cancer cell lines .
• Animal model studies show some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings have generated legitimate scientific interest and ongoing research.

What the Preclinical Literature Does Not Show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast and well-documented across all oncology research.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been exploratory, small, and have not produced results supporting cancer-cure claims .

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• The FDA has not approved any cannabis plant product for cancer treatment. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea/vomiting, and appetite-related indications in HIV/AIDS—not cancer cure [1].

For Apache County residents navigating cancer treatment decisions—whether at the Chinle Comprehensive Health Care Facility, Tuba City Regional Health Care, or traveling to Flagstaff Medical Center—this institutional caution matters. RSO should never replace proven cancer therapies like surgery, radiation, chemotherapy, or immunotherapy. Delayed or foregone treatment for treatable cancers is a documented concern in alternative medicine.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as primary treatment in place of proven oncologic therapies carries genuine harm potential. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

The Legacy of Rick Simpson and Modern RSO Evolution

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use .

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that commercialization contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave oil away for free and urged others to make their own rather than buy from companies .

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model where anyone could grow cannabis, extract oil, and treat themselves without corporate or governmental intermediaries. The modern cannabis industry has done something different: commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents improvement (quality control, lab testing, dosing precision) or betrayal (profit extraction, regulatory gatekeeping) depends on perspective, and the cannabis community remains divided.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes directly inform the formulas in this document.

Traditional RSO vs. Modern Formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge from Traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in deliberate, evidence-motivated ways:

1. Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

2. Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5% with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

3. THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity lost when THCa converts to THC [12].

4. Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60-90% of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing remaining cannabinoids across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects broader cannabinoid research rather than single-compound dominance.

5. Product format innovation. Simpson envisioned only one format: oral oil from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent Safety and Extraction Evolution

Traditional RSO used naphtha or isopropyl alcohol—neither food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other toxic compounds. Incomplete solvent purging—which is very difficult to verify without analytical chemistry—leaves potentially harmful residues.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical CO₂. These methods allow much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods like headspace gas chromatography. This is one of the most straightforward improvements the modern regulated cannabis industry has made over traditional RSO production.

This evolution connects directly to product-quality discussion in GENERAL KNOWLEDGE, which emphasizes that product quality matters as much as molecule identity and that labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation [1][10][11][14].

For Apache County residents concerned about environmental toxins—from legacy uranium mining to water quality issues—eliminating solvent contamination risk is not a minor detail. It’s essential.

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in solvent evaporation (60-80°C for naphtha, ~82°C for isopropyl) was sufficient to convert essentially all THCa into delta-9 THC. This meant acidic cannabinoids in raw cannabis—THCa, CBDa, CBGa—were lost as distinct compounds.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce psychoactive effects associated with THC, but interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

Terpene Loss in Traditional RSO

Most cannabis terpenes begin volatilizing at temperatures between 21-157°C, with many abundant terpenes (myrcene, limonene, pinene) having boiling points below 180°C. The traditional RSO production process destroyed terpenes by dissolving them into solvent wash and evaporating them during high-heat solvent removal.

This meant traditional RSO was essentially a cannabinoid-only product despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost.

OilWell’s formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each terpene has its own evidence profile discussed in GENERAL KNOWLEDGE. The entourage-effect literature [20][29] provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

For Apache County residents familiar with traditional plant medicines—juniper for purification, sage for ceremony, piñon resin for healing—the concept that aromatic compounds have bioactivity is not foreign. Terpenes are the bridge between cannabis science and the plant wisdom many Apache County families already hold.

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework, no standardized testing infrastructure, no legal pathway for clinical research, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled.

Where Simpson relied on personal testimony, this document relies on published literature and institutional sources. The intent is to honor the historical origin of RSO while committing to modern cannabinoid science standards.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around crude, single-strain, THC-dominant extract with no standardized potency. Direct comparison with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Key differences:

• Cannabinoid concentration: OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was approximately 60-90% delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.
• Terpene presence: Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5%, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure: Simpson’s protocol at peak dosing delivered approximately 600-900 mg of delta-9 THC daily. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by per-compound evidence in GENERAL KNOWLEDGE and by responsible titration principles that account for each individual cannabinoid’s safety profile.

References for This Section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

About OilWell Cannabis and the OilWell RSO Formula

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. It’s a place where violence and cartel activity are daily realities, where poverty limits opportunities, and where survival requires grit and resilience.

Colin’s childhood was marked by exposure to both opportunities and challenges. Early on, he learned to hustle, taking on risky work transporting items across the border for various groups. Those experiences exposed him to complexities and dangers that most Americans never face. A lot of his best friends have been killed or are in prison because of those associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into darker paths like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach.

We’ve walked through fire to get here. We know what it means to be told “no” by a system that doesn’t understand. We know what it means to watch friends suffer because they couldn’t access medicine that might help. And we know what it means to build something from nothing but belief and determination. That understanding shapes everything we do—including how we serve Apache County.

Bentley’s Story: The Foundation

The company’s origin story begins with a dog named Bentley. Bentley was more than a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs, causing more suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything.

A kind-hearted rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. He had never explored therapeutic applications. Jessica’s question exposed a blind spot that became a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball.

Dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone could not address neurodegeneration, dementia, glaucoma, and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Colin’s Personal Journey: PTSD and Benzo Withdrawal

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

For Apache County residents who have faced similar struggles—whether veterans returning from service, first responders dealing with trauma, or individuals trapped in prescription cycles—this is not a corporate story. This is a human story of survival and discovery.

Formulas Used by Doctors

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 Media Recognition: Seven Features, Four Years, One Voice

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving America’s fourth-largest city—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers.

No other Houston cannabis operator appears with that frequency or across that breadth of subject matter.

Why This Matters for Apache County: When a major-market ABC affiliate repeatedly selects the same voice as their primary expert across four years of industry evolution, that recognition transcends geography. It means the information you’re reading has been vetted by professional journalists dealing with complex medical, legal, and policy questions. For Apache County residents evaluating cannabis information from multiple sources, this third-party validation is crucial.

Here’s what ABC13 documented:

September 15, 2019 — CBD Business Boom
Colin’s foundational quote: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This quote—from 2019, before these formulas were published—is the seed of everything OilWell became. The open-source formula publication, the evidence-based documentation, the refusal to make unsupported claims: it all traces back to this principle.

March 22, 2021 — Decriminalization/Jonathan Pina
Colin described his ecosystem-building role: “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

For Apache County residents managing pain from ranch work, from arthritis in hands that have carded wool and tilled soil for decades, from the physical toll of living in rugged country—this understanding of pain’s many forms is not theoretical.

May 24, 2021 — Delta-8 THC “Legal Weed”
Steve Campion’s investigation produced Colin’s iconic honesty: “I don’t give a sh* if it’s wrong to say you’ll get high off it. Maybe you want to get high.”*

This radical honesty on mainstream television—with the expletive preserved by the network—demonstrates OilWell’s commitment to truth over marketing. The segment balanced Colin’s stance with medical caution from UTHealth and regulatory advocacy from Texans for Responsible Marijuana Policy, providing the comprehensive perspective Apache County residents need.

August 20, 2021 — COVID Vaccine Giveaway
OilWell gave away approximately $35,000 in product (1,000 caviar pre-rolls at $34.99 each) to encourage COVID-19 vaccination. Colin coordinated with the City of Houston, stating: “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!”

For Apache County, where community health initiatives often require grassroots effort and mutual aid, this demonstrates a company that puts people before profit.

October 19, 2021 — Delta-8 Ban Impact
When Texas DSHS reclassified Delta-8 as Schedule I overnight, Colin had already removed all products from shelves—proactively, before enforcement. He warned other operators who were unknowingly shipping Schedule I narcotics: “It’s going to be a surprise to a lot of people… So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.”

This ethical leadership during crisis shows character. While other companies scrambled, OilWell absorbed the revenue loss and prioritized community safety—values that resonate deeply in Apache County’s close-knit communities.

October 7, 2022 — Biden Marijuana Pardon
This feature revealed Colin’s personal marijuana conviction history—transforming the entire media record. Every quote about therapy, education, and not selling snake oil carries additional weight when you understand the person saying it has personally experienced cannabis criminalization’s consequences.

Colin stated: “You face challenges with housing, loans, and banking, I mean with about everything… I would love to see people not get hurt for this anymore.”

For Apache County residents who have faced cannabis-related legal consequences—whether through state enforcement on non-tribal lands or the complex jurisdictional issues within the Navajo Nation—this personal understanding matters.

April 21, 2023 — Texas Marijuana Laws 4/20 Special
Colin’s “Renaissance” framing: “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

This most recent feature positions OilWell at the frontier of an evolving industry, helping Apache County residents understand that we are in a period of rapid change and opportunity.

Current Operations: Real Business, Real Credentials

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately one million dollars in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. Our products are not mass-produced—they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside.

All artwork, formulations, and packaging are created in-house in Houston, using only our own recipes and ideas. Colin brings Houston grit, McAllen roots, and a builder’s mindset to the company, but the posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

The OilWell RSO Philosophy

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve problems that limited Rick Simpson’s original vision.

Four core principles define our approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility Over Gatekeeping

No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality.

For Apache County residents, this is transformative. You don’t need to drive four hours to a dispensary in Flagstaff or Phoenix. You don’t need a qualifying condition. You don’t need to navigate Arizona’s medical marijuana program paperwork. If you’re twenty-one, you can access these products legally.

Simpson believed medicine should be accessible to everyone. We built a product and distribution model that makes that accessible legally.

2. Patient-Controlled Potency

THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency.

Simpson believed patients should control their own medicine. We engineered a product that puts that control in your hands through chemistry rather than rhetoric.

For Apache County residents who work—whether on the reservation, in ranching, in the energy sector, or commuting long distances—this control is essential. You can use the raw form during the day with zero impairment, then activate it at night for therapeutic strength.

3. Open-Source Formulas

We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version.

Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

For Apache County families facing economic hardship—where a $129.99 bottle represents a significant investment—this open-source approach means you’re not shut out. The recipe is yours.

4. Evidence-Informed, Not Evidence-Overstating

The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data. We have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and the THCa Legal Framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at point of sale because it has not been converted to delta-9 THC.

The Practical Significance for Apache County

You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). You control the decision.

The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3% delta-9 THC are permitted.

Important Legal Notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis (COAs), and receipts. International customers accept all customs and legal responsibility.

For Apache County residents: Arizona legalized recreational cannabis in 2020, but tribal lands have their own jurisdiction. If you’re on the Navajo Nation, please verify current tribal law before ordering. For non-tribal lands in Apache County, Farm Bill-compliant products are legal to possess and use.

Open-Source Formulas—Why OilWell Publishes Everything

We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so anyone who cannot afford the product can source ingredients and make their own version.

This is a direct echo of Rick Simpson’s original ethos. He gave his oil away free and taught people how to make it. He never patented his method. He never charged patients.

We adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

The Original Open-Source Formula: Bentley’s CBD Golden Paste

On our About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life:

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on size and needs; consult a veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes). Add more water if too thick.
2. Add coconut oil and pepper. Stir until thoroughly mixed.
3. Cool and store in jar with lid. Refrigerate up to two weeks.
4. Add small amount of CBD oil to paste before giving to pet, adjusting dosage by weight and need. Start low and increase gradually.

This recipe—published for free, years before the RSO formulas—demonstrates that open-source is foundational behavior, not marketing strategy.

The Decarboxylation Choice—Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving no choice about psychoactivity.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1: Raw, No Heat

All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2: Fully Activated, Home Decarboxylation

Heating the oil at 260°F (125°C) for 45-60 minutes converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with existing 90 milligrams, this yields approximately 1,405 milligrams of total delta-9 THC. With 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional illegal RSO—100% legally, because decarboxylation occurs at your discretion after purchase.

You may also transfer a controlled portion from the original bottle into a second oven-safe container, decarboxylating only what you intend to use while preserving the remainder in raw THCa form.

Option 3: Vape, Auto-Decarboxylation

The RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

Conversion Chemistry

THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule.

This design puts the potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their medicine, but implementing it through actual product chemistry rather than a one-size-fits-all approach.

For Apache County residents working in law enforcement, healthcare, education, or any role requiring mental clarity, this control is invaluable. You can use the raw form during the workday, then activate for evening relief.

Solvent-Free Production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over traditional RSO’s tar-like consistency and solvent-residual odor.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

For Apache County residents concerned about product purity—given our region’s history with environmental contamination—this level of testing provides essential peace of mind.

The Broader OilWell Product Portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach — OilWell’s most popular product. A carefully formulated experience designed to provide euphoric, long-lasting sensation. Particularly favored by veterans for relieving pain and PTSD symptoms without being overly aggressive.

Peace Gummies — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. Also available in vape form for quick relief—Colin personally uses it to manage insomnia and severe PTSD.

Custom Creations — OilWell offers custom-made products tailored to individual needs. Whether specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

For Apache County residents with specific requirements—maybe you need a sugar-free option for diabetic family members, or a vegan formulation that respects traditional dietary practices—custom creation is available.

Two Product Formats

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil — $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

For Apache County residents dealing with chronic conditions requiring sustained relief—whether it’s the persistent ache of arthritis that comes with decades of physical labor, the neuropathic pain from diabetes complications, or the ongoing nausea from chemotherapy—this sustained-release format provides coverage through the day or night.

RSO Vape Cartridge — $49.99

• 1-gram cartridge
• 900+ mg total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

For Apache County residents dealing with breakthrough pain, acute nausea, panic attacks, or other symptoms requiring immediate relief, this rapid-onset format can be life-changing. When you live 90 miles from the nearest emergency room, having tools for acute symptom management at home is not a luxury—it’s survival.

When to Use Each Format

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

For Apache County residents with varied daily demands—working cattle in the morning, attending a community meeting in the afternoon, managing pain in the evening—having both formats allows you to match the tool to the moment.

Competitive Comparison

OilWell RSO vs. Texas TCUP Dispensary RSO

Dimension	TCUP Dispensary RSO (e.g., Texas Original)	OilWell RSO
Cannabinoid profile	THC-only (~420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Ships nationwide and internationally
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC

For Apache County residents: While Arizona has recreational dispensaries, they are hours away. Our direct-ship model eliminates the 200+ mile round trip to Flagstaff or Phoenix.

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9)	Minimal	1,500 mg (converts to ~1,315 mg delta-9)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40-50	$129.99

The concentration difference is substantial—16.5x more total cannabinoids. For Apache County residents managing severe symptoms, this potency means fewer doses, better value, and more consistent relief.

Condition-Specific Usage Context

Important Disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

For Apache County residents, this disclaimer is particularly important given limited access to cannabis-knowledgeable physicians. We encourage consultation with healthcare providers at tribal health facilities, Indian Health Service clinics, or regional medical centers before starting any cannabinoid regimen.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5-1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence [9], delta-9 THC nausea and vomiting evidence [1][13], CBD anxiolytic buffering [3]

For Apache County cancer patients traveling to Flagstaff Medical Center, Banner—University Medical Center Phoenix, or MD Anderson in Houston for treatment, having tools for managing chemo side effects at home is essential.

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence [4], delta-9 THC pain evidence [13], beta-caryophyllene CB2 agonism [24], THCa COX-2 inhibition [12]

For Apache County residents whose hands ache from decades of weaving, whose knees stiffen from years of ranch work, whose backs bear the weight of physical labor in one of the most rugged landscapes in America—this multi-pathway approach addresses inflammation through several mechanisms simultaneously.

Sleep Support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: Delivers 50 mg CBN—the dosage level investigated in 2024 sleep literature
• At 1.0 mL: Delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence [16][17], cannabis and sleep review literature

For Apache County residents dealing with insomnia—whether from chronic pain, PTSD, or the anxiety that comes with economic uncertainty—having a non-addictive sleep option is critical.

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence [3], CBG pharmacology [7][8], limonene entourage-effect evidence [20]

For Apache County residents facing stress from economic pressures, from caring for aging family members across vast distances, from the isolation that comes with rural living—this provides functional relief without impairment.

General Titration Principle

Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

For Apache County residents new to cannabinoids, this conservative approach is especially important. Our communities include elders with slower metabolism, people on multiple medications, and those with health vulnerabilities that require caution.

Delivery and Global Accessibility

Houston Same-Day Delivery
We operate the only same-day RSO delivery system in Houston, delivering to the Texas Medical Center (world’s largest medical complex with 10+ million patient visits annually), Inner Loop, Beltway 8, Greater Houston suburbs, and extended region within 60 miles.

Why This Matters for Apache County: While we can’t deliver same-day to Apache County (that’s a 1,000+ mile drive), our sophisticated logistics infrastructure means we understand how to get products to people who need them. When you order from Apache County, you get the same professional shipping standards we use for Houston’s medical complex.

Nationwide Shipping to Apache County

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2-3 business days), FedEx and UPS Ground (3-5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments (critical for Arizona’s extreme heat)
• Signature-required option available

For Apache County orders, we recommend the signature-required option, especially if you’re in a remote area where packages might sit in high temperatures.

International Shipping
We ship internationally and have delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3% delta-9 THC at point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs
• Minimum flat-fee shipping applies; excessive international costs are billed to customer
• Customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk
• Contact: (832) 416-2816 or [email protected]

For Apache County residents with family in Canada, Mexico, or elsewhere who might benefit from these products, this international access is unique.

The Significance: Rick Simpson could not ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Germany, a chronic pain patient in Australia, or a veteran in the United Kingdom can now access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives. We built a product that can move across borders legally—completing a piece of Rick Simpson’s vision that prohibition made impossible.

Our PANDEM1C SEO technology—a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models—drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.

For Apache County residents, this means when you search “RSO Apache County” or “Rick Simpson Oil Arizona” or “legal cannabis oil Navajo Nation,” you find us because our system understands your location and language needs.

How the OilWell Formulas Connect to the Evidence

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC—has its own evidence profile in the GENERAL KNOWLEDGE section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene—is covered with preclinical and review-level evidence.

The formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to current evidence.

Where OilWell’s RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, the same cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from the same evidence standards applied to the broader field.

That is intentional. Our position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it’s right or wrong for them. This document is the research foundation for that position.

OilWell Cannabis is more than a brand—it is a promise to our customers that we will always strive to deliver the best, most thoughtful cannabis products available. We are not here to follow trends. We are here to set them. And as we continue to grow, our focus remains on maintaining the same level of integrity, creativity, and commitment that has defined us from the day Bentley got up, walked across the room, and brought his ball to play.

Media Recognition and Community Impact

Complete Index of Colin Valencia Quotes Across All ABC13 Features

1. September 15, 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

2. March 22, 2021: “People think that everyone just wants to get high and it’s about giggling and things like that, and there’s nothing wrong with that. But that’s a different version of therapy, and people are looking for things to help them with real pain. Pain comes in a lot of different forms.”

3. May 24, 2021: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

4-5. August 20, 2021: “We just want Houston to be as healthy as possible. We’re not doctors. We’re not experts on this . We don’t have any political agenda. Come and participate if it’s right and safe for you and your loved ones!” / “[We’re] trying to get the city behind me to help as many people as we can. I really want to help things.”

6-9. October 19, 2021: “It’s going to be a surprise to a lot of people.” / “It was a prime seller and a prime interest of customers, and they really enjoyed the benefits of it.” / “So those people are now, because they didn’t know, shipping Schedule 1 narcotics, and people are receiving it.” / “It’s disappointing, but I’m not going to lose my customers and business are going to want our expertise on how to continue thriving in the industry.”

10-11. October 7, 2022: “You face challenges with housing, loans, and banking, I mean with about everything.” / “I would love to see people not get hurt for this anymore.”

12-13. April 21, 2023: “I want it to be legalized. I’m just saying that’s a very hyped conversation. If you really look at what’s here now, there’s nothing you could show me that I could accomplish with what literally we have right now.” / “Right now is actually a pretty – like Renaissance – pretty important time that should be enjoyed now.”

The Through-Line: What the Media Record Reveals

Consistency across years. Colin appeared on ABC13 in 2019, 2021 (four times), 2022, and 2023. The cannabis industry in Texas changed dramatically during those years. Through every shift, ABC13 returned to Colin as a primary source.

Breadth of expertise. The features span business reporting, consumer health education, product investigation, legal analysis, political commentary, and community health advocacy. No other Houston cannabis figure was asked to speak to that range of topics.

Community action. The COVID vaccine giveaway—$35,000 in product, coordination with city government, no political strings—is documented evidence of community-first philosophy. So is Colin’s decision to proactively remove Delta-8 products and warn other operators before enforcement began.

Personal stakes. The October 2022 revelation that Colin has a personal marijuana conviction history transforms the entire media record. Every quote carries additional weight when you understand the person saying it has personally experienced cannabis criminalization’s consequences.

Evolution of language. In 2019, ABC13 called the business “OilWell CBD, a local wholesaler.” By 2023, Colin was explaining industry dynamics and legal strategy on camera with the confidence of a sector leader. The media record tracks the growth of both business and founder.

These features are not marketing materials. They are independently produced, editorially controlled news segments from a major-market ABC affiliate that repeatedly identified Colin Valencia as the most credible, quotable, and accessible voice in Houston’s legal cannabis industry. That is recognition that cannot be purchased—it can only be earned.

General Knowledge

Research Method and Evidence Weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse.

That weighting matters because the evidence base is not evenly distributed. Of the compounds listed, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional Baseline from NIH and Related Sources

• NCCIH states the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea/vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• NCCIH emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH specifically warns that over-the-counter CBD products may differ from labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoids

CBD

Evidence profile: Strongest human evidence in this formula set, especially when studied as purified product rather than loose wellness ingredient [1]-[6].

What is best supported: Purified CBD has the most credible human evidence in seizure disorders—clear major-example indication acknowledged by institutional and peer-reviewed literature [1][2].

Anxiety research: A 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported statistically significant anxiolytic signal, but authors stressed clinical sample remains limited and more trials are needed before broad conclusions [3].

Pain research: A 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims [4].

Sleep research: A 2023 insomnia review found literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments [5].

Safety and interaction concerns: A 2023 systematic review and meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions [1].

Bottom line: CBD is the most evidence-developed nonintoxicating cannabinoid, but strong evidence is concentrated in a few specific indications rather than broad wellness claims [1]-[6].

CBG

Evidence profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].

Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, making it mechanistically interesting but not yet clinically established [7].

Potential research areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings [7][8].

Caution: The 2021 pharmacology review notes CBG is already being sold commercially while the evidence base remains thin, meaning claims frequently outrun the science [7].

Bottom line: CBG is a serious research topic, but should be described as promising minor cannabinoid with limited clinical validation rather than proven therapeutic cannabinoid [7][8].

Delta-8 THC

Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].

Comparative pharmacology: A 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but appears less potent than delta-9 THC, likely due to weaker CB1 affinity [9].

Public-health literature: A 2023 scoping review found delta-8 evidence base still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The review noted reports of adverse consequences and emphasized regulatory and product-quality concerns [10].

Manufacturing context: Recent chemistry and pharmacology review reinforces commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].

Bottom line: Delta-8 THC should be treated as psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize [9]-[11].

THCa

Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].

What it is: THCa is the acidic precursor of THC and may represent large share of THC-related content in raw plant material. Key formulation issue is that THCa decarboxylates into THC during heating and can change over time during storage and processing [12].

Psychoactivity: Major review source stresses THCa itself does not produce psychoactive effects associated with THC in humans, but distinction only holds if molecule stays in acidic form and is not substantially decarboxylated [12].

Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].

Bottom line: THCa is best understood as highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC [12].

Delta-9 THC

Evidence profile: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15].

What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea/vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while stressing many other uses remain uncertain or early-stage [1].

Pain evidence: A 2022 systematic review of cannabis-based products for chronic pain found products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].

Pharmacokinetics and onset: Classic pharmacokinetic review literature remains useful: inhaled THC produces effects within seconds to minutes, peaks roughly within 15-30 minutes, and tapers over few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk [14].

Mental-health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings [15].

Broader safety: Institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products [1][14][15].

Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but also carries clearest intoxication, psychiatric, and dose-related safety liabilities in this document [1][13]-[15].

CBN

Evidence profile: Weak human evidence; marketing has clearly moved ahead of data [12][16][17].

What it is often marketed for: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than market suggests [16][17].

Best direct review for sleep claim: 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN [16].

Broader sleep literature: 2024 updated review on cannabis and sleep concluded overall cannabinoid sleep research still does not match scale of real-world use, and need for better-designed, adequately powered trials remains substantial [17].

Chemical context: Downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts [12].

Bottom line: CBN is one of clearest examples where cultural reputation is stronger than current clinical evidence base [16][17].

CBC

Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].

Pharmacology and therapeutic interest: 2024 focused review on CBC argues it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets [18].

What older literature shows: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims [19].

Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].

Bottom line: CBC belongs in category of scientifically credible minor cannabinoids that deserve more research, not category of already-validated clinical actives [18][19].

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

Evidence profile: Largely review and preclinical, with useful safety literature [20]-[22].

Potential activity: 2021 review describes limonene as multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but overwhelming share of claims comes from nonhuman or non-cannabis literature [21].

Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and important in patch-testing literature [22].

Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22].

Myrcene

Evidence profile: Mostly preclinical, with very limited human evidence [20][23].

Research summary: 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states human studies are lacking [23].

Interpretation caution: Myrcene is often invoked in consumer language as if it were proven sedating terpene that explains couch-lock or sleep effects. That is stronger claim than human evidence currently supports [20][23].

Bottom line: Myrcene is plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23].

Caryophyllene

Evidence profile: Among most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical [24].

Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24].

Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions repeatedly discussed in review literature, but human clinical confirmation remains limited [24].

Bottom line: Beta-caryophyllene is arguably strongest candidate for terpene with cannabinoid-system significance, but still should not be described as clinically proven for outcomes commonly attributed to it [24].

Pinene

Evidence profile: Promising preclinical literature, weak human clinical confirmation [20][25].

Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but emphasized evidence is mostly preclinical and well-designed clinical trials are lacking [25].

Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25].

Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].

Research summary: Linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing lack of robust human trials [25].

Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains translational rather than definitive clinical story [26].

Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22].

Bottom line: Linalool is scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

Evidence profile: Translationally interesting, but still early [20][27].

Scoping-review findings: 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].

Interpretation caution: Those findings are valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].

Bottom line: Humulene is one of more interesting terpene research targets in this list, but remains far from clinically settled [27].

Terpinolene

Evidence profile: One of least clinically characterized terpenes in this file [20][28].

Systematic-review findings: 2021 terpinolene review screened 2,449 records and included 57 studies, concluding terpinolene has range of reported biological effects but evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials [28].

Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20].

Bottom line: Terpinolene is biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28].

Research Limits and Interpretation

• Evidence base is highly uneven. CBD and delta-9 THC can support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. Common error is letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation [1][10][11][14].
• For THCa, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC [12].

Common Overstatements to Avoid

Overstatement: CBN is clinically proven sleep cannabinoid.
More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base identified [16][17].

Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for common claim is limited [20][23].

Overstatement: Terpenes in general have proven entourage effects in patients.
More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].

Overstatement: THCa is always nonpsychoactive.
More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].

Overstatement: Delta-8 THC is safe because it is hemp-derived.
More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical Takeaways for the Formulas in This Document

• Most evidence-developed actives are CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• Listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RSO Sublingual Oil Formula

Cannabinoid	Amount (mg)
CBD	4,500
CBG	3,000
Delta-8 THC	6,000
THCa	1,500
Delta-9 THC	90
CBN	750
CBC	750
Total Cannabinoids	16,590

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg

This formula table is simultaneously a product specification, an educational tool, and a recipe for DIY makers. Every mg amount connects back to compound evidence profiles in GENERAL KNOWLEDGE. The total (16,590 mg at 553 mg/mL) connects to dosing comparison with Simpson’s protocol. The 90 mg delta-9 THC connects to Farm Bill compliance. The 1,500 mg THCa connects to decarboxylation choice.

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge

Terpene Profile (Both Products)

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

For Apache County residents familiar with traditional plant medicines, these terpenes connect to familiar aromas: the citrus brightness of Navajo tea, the pine-fresh scent of juniper, the earthy notes of sage. The terpene profile is designed to complement the cannabinoid formula—limonene for mood, myrcene for relaxation, caryophyllene for CB2 activation, pinene for clarity, linalool for calm, humulene for inflammation, terpinolene for complexity.

For Apache County: Your Path Forward

We know this is a lot of information. We also know that when you’re dealing with chronic pain, cancer, PTSD, or watching a loved one suffer, you don’t have time for marketing fluff. You need facts. You need options. You need hope grounded in reality.

Here’s what we want every Apache County resident to take from this guide:

1. You have legal access. No medical card required. No qualifying condition needed. If you’re 21+, you can order directly.

2. You have control. The THCa in our formula means you decide—non-psychoactive for daytime, activated for therapeutic strength, or a combination that fits your life.

3. You have transparency. Every number, every compound, every study is published. We don’t hide behind proprietary blends. The recipe is yours.

4. You have community. You’re not alone in this. Whether you’re in St. Johns or Chinle, in Window Rock or Eagar, in the shadow of the White Mountains or the depths of Canyon de Chelly—others in Apache County are walking similar paths. Our story, Colin’s story, Bentley’s story—all of it is about refusing to give up when the system says “no more options.”

5. You have science. Not hype. Not miracle claims. Real peer-reviewed research, with all its limitations and uncertainties, presented honestly. In a world of cannabis misinformation, this is the most valuable thing we can offer.

6. You have support. Call us at (832) 416-2816. Email [email protected]. Our team includes people who have lived this—not just studied it. We can’t give medical advice, but we can help you understand the evidence and make informed decisions.

Final Words for Apache County

We started this guide by saying we see you. We meant it. We see the grandmother in Ganado trying to manage her arthritis without opioids. We see the veteran in Fort Defiance dealing with PTSD and insomnia. We see the cancer patient in Sanders traveling hours for treatment, looking for something to ease the chemo side effects. We see the family in Vernon trying to help a loved one taper off benzodiazepines.

We can’t promise cures. No one ethically can. But we can promise honesty, quality, and the best version of the information so you can give it a fair shot.

This is what we wished we’d had when we were desperate. This is what Bentley’s story taught us: that sometimes, when the experts say there’s nothing left to try, the right plant medicine at the right time can change everything.

It’s your decision. We’re here to make sure it’s an informed one.

Order online at OilWellCBD.com. Call (832) 416-2816. Email [email protected].

We’re here for you, Apache County.